Sipuleucel-T for the treatment of prostate cancer: Novel insights and future directions

Catherine E. Handy, Emmanuel S. Antonarakis

Research output: Contribution to journalArticlepeer-review

108 Scopus citations


Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product approved by the US FDA. It was approved for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer after it was shown to provide a survival advantage. Additional studies have examined its use in other clinical settings and in combination with other approved and investigational immunotherapy agents. This review will discuss the pivotal trials leading to approval, will outline some of the biomarkers associated with its efficacy and will review some of the ongoing combination strategies. Maximizing the efficacy of sipuleucel-T through better patient selection or through combination approaches remains the challenge of the future.

Original languageEnglish (US)
Pages (from-to)907-917
Number of pages11
JournalFuture Oncology
Issue number10
StatePublished - Apr 2018
Externally publishedYes

Bibliographical note

Funding Information:
This work was partially supported by NIH grant P30 CA006973 (ES Antonarakis) and Conquer Cancer Foundation/Bristol-Meyers Squibb Young Investigator Award (CE Handy). ES Antonarakis is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Clovis and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis and Merck; and he is the coinventor of a biomarker technology that has been licensed to Tokai and Qiagen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Publisher Copyright:
© 2018 2018 Future Medicine Ltd.


  • biomarkers
  • cancer vaccine
  • castration-resistant prostate cancer
  • immunotherapy
  • prostate cancer
  • sipuleucel-T


Dive into the research topics of 'Sipuleucel-T for the treatment of prostate cancer: Novel insights and future directions'. Together they form a unique fingerprint.

Cite this